Physician profile
Mark G Christopher
NPI 1699729913
$4,326.30
in general payments reported to CMS, 2019-2025
25 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $185 · 2022: $622 · 2023: $1,000 · 2024: $787 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Education: $83.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.55 |
| Education | $83.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.44 | 2019-2025 | Viberzi, Linzess, Skyrizi |
| Janssen Biotech, INC. | $888.33 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $567.08 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.31 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $238.27 | 2022-2024 | Dupixent |
| Genzyme Corporation | $219.26 | 2022-2025 | |
| Pfizer INC. | $194.92 | 2019-2025 | |
| Gilead Sciences, INC. | $144.14 | 2019-2024 | |
| Madrigal Pharmaceuticals | $112.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $58.56 | 2019 | |
| Ardelyx, INC. | $51.80 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $50.90 | 2024 | |
| Nestle Healthcare Nutrition INC. | $48.65 | 2023 | |
| Braintree Laboratories, INC. | $37.68 | 2019-2023 | Suflave |
| Organon LLC | $35.15 | 2023 | Renflexis, Hadlima |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $34.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.57 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $27.86 | 2022-2023 | Linzess |
| Merck Sharp & Dohme LLC | $18.19 | 2019 | |
| Lucid Diagnostics INC. | $14.59 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.50 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $12.96 | 2020 | |
| Ucb, INC. | $12.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| Shire North American Group INC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.